TY - JOUR
AU - Morales, Daniel R.
AU - Ostropolets, Anna
AU - Lai, Lana Yin Hui
AU - Sena, Anthony G.
AU - DuVall, Scott L.
AU - Suchard, Marc
AU - Verhamme, Katia
AU - Rjinbeek, Peter
AU - Posada, Jose D.
AU - Ahmed, Waheed
AU - Alshammari, Thamir M.
AU - Alghoul, Heba
AU - Asler, Osaid
AU - Areia, Carlos
AU - Blacketer, Clair
AU - Burn, Edward
AU - Casajust, Paula
AU - You, Seng Chan
AU - Dawoud, Dalia M.
AU - Golozar, Asieh
AU - Gong, Mengchun
AU - Jonnagaddala, Jitendra
AU - Lynch, Kristine E.
AU - Matheny, Michael E.
AU - Minty, Evan P.
AU - Nyberg, Fredrik
AU - Uribe, Albert
AU - Recalde, Martina
AU - Reich, Christian G.
AU - Scheumie, Martijn
AU - Shah, Karishma
AU - Shah, Nigam H.
AU - Schilling, Lisa M.
AU - Vizcaya, David
AU - Zhang, Lin
AU - Hripcsak, George
AU - Ryan, Patrick
AU - Prieto-Alhambra, Daniel
AU - Talita, Duarte-Salles
AU - Kostka, Kristin
PY - 2022
DA - January
TI - Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe
JO - Journal of Asthma
DO - https://doi.org/10.1080/02770903.2021.2025392
AB - Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma. Methods: We included nine databases contributing data from January-June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients (‘diagnosed’ and ‘hospitalized’) based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions. Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6%-8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95%CI 5.7-6.8) to 18.5% (95%CI 18.2-18.8) in the diagnosed cohort and 5.2% (95%CI 4.0-6.8) to 20.5% (95%CI 18.6-22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95%CI 1.8-2.4) to 16.9% (95%CI 13.8-20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15%-30% of hospitalized COVID-19 asthma patients. Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients.
PB - Taylor and Francis
UR - https://discovery.dundee.ac.uk/en/publications/9d4eee34-4888-4921-a1ee-fd2233fdb9bf
KW - Coronavirus (COVID-19)
ER